In this insightful podcast episode, Miguel Regueiro, MD, Chief of the Digestive Disease Institute at Cleveland Clinic, shares his journey from a young physician-in-training to one of the most respected leaders in gastroenterology today. He explores the evolution of the medical home model for patients with inflammatory bowel disease (IBD) — a paradigm that places coordinated, multidisciplinary care at the center of managing complex chronic illness.
Author: Abhay Panchal
The FDA has escalated a Class I recall of Medtronic’s Bravo reflux testing system after 33 reports of serious injuries linked to the device. The Bravo system, commonly used to diagnose GERD, involves placing a pH-sensing capsule in the esophagus to detect acid levels. However, a manufacturing defect—specifically, misapplied adhesive—may cause the capsule to dislodge from the delivery system or fail to attach properly to the esophageal wall. The result? Risk of airway obstruction, tissue perforation, and internal bleeding. While no deaths have been reported, Medtronic and its Given Imaging unit have urged providers to quarantine affected lots and return…
In his latest Ground Truths essay, Eric Topol unpacks a wave of breakthroughs placing the gut-brain axis at the heart of modern medicine. From gut-derived T cells triggering neuroinflammation to H. pylori proteins blocking amyloid plaques, the gut is no longer just about digestion—it’s influencing immunity, neurodegeneration, and metabolic health. Topol also spotlights a surge in next-gen GLP-1s—oral, injectable, even triple agonists—being studied for everything from obesity and diabetes to sleep apnea and Alzheimer’s. The future of brain and immune health, he argues, may be driven not by the brain itself, but by what we feed and foster in our…
In a groundbreaking move, Cosmo Pharmaceuticals and Rush University Medical Center will launch the first clinical study connecting Medtronic’s AI-powered GI Genius™ module with Apple Vision Pro. The upcoming July 2025 trial, led by renowned gastroenterologist Dr. Irving Waxman, explores how spatial computing could redefine real-time colonoscopy workflows — letting endoscopists view AI-generated insights without diverting attention from the procedure. Could this fusion of clinical AI and immersive tech be the new standard in GI medicine?
Sap Sinha is not your typical GI leader—and that’s exactly why I wanted him on The Scope Forward Show. With a background in economics, consulting, and digital health, Sap brings a fresh, systems-level lens to a specialty that often struggles with operational inertia. As COO of Allied Digestive Health, he’s overseen 4x growth, reengineered core infrastructure, and redefined what scalability looks like in GI. This conversation is one of the most practical and thought-provoking explorations we’ve had yet on building the future of gastroenterology. Full disclosure: Allied Digestive Health is a client of my company, NextServices. Watch the episode. Top Insights from the Interview:1.Middleware…
What began in a 10×12 closet has grown into a national movement. Dr. Casey Chapman, now Chief Medical Officer of GI Alliance, is spearheading a transformation in community-based GI research. With over 1,100 physicians, GI Alliance is embedding clinical trials into standard care — not as an afterthought, but as a core function. Its new partnership with Iterative Health supports 21 sites and 80+ trials, alleviating the administrative burden on clinicians and research staff.
A new wave of FDA-cleared AI tools is transforming facial analysis into a clinical instrument—measuring vital signs like heart rate, respiratory rate, blood pressure, and even predicting patient prognosis. From FaceAges, which correlates perceived age with cancer outcomes, to PanopticAI and FaceHeart, which turn cameras into non-contact monitors, AI is enabling personalized and frictionless diagnostics. These technologies offer speed, accessibility, and comfort—but also raise concerns about privacy and clinical validation. As facial data becomes a lens into systemic health, clinicians and regulators will need to balance innovation with oversight. The future of patient monitoring may start not with touch—but with…
Gateway Gastroenterology, in partnership with USPI, has broken ground on a new 28,000-sq-ft endoscopy center in Chesterfield, Missouri. The two-story facility—featuring four procedure rooms and clinic offices—is set to open in spring 2026. Led by Russell as general contractor, with design by E4H Architecture and engineering by Garver and Stock & Associates, the project expands access to advanced GI care in the region. This follows Gateway’s No. 1 state ranking for outpatient endoscopy by U.S. News & World Report—for the second year in a row.
A new Phase 3 trial from Norway suggests fecal microbiota transplantation (FMT) may be noninferior to vancomycin for first-episode Clostridioides difficile infection (CDI). Conducted across 20 hospitals, the trial showed a 66.7% cure rate with FMT vs. 61.2% with vancomycin, without increased adverse events. While still controversial in the U.S., this study signals FMT’s growing therapeutic credibility. Is this the beginning of a shift in first-line CDI care?
In a recent World Journal of Gastroenterology letter, gastroenterology researchers led by Prof. Vladislav Tsukanov explore whether artificial intelligence is truly ready to take center stage in colorectal cancer screening. While AI-enhanced colonoscopy improves polyp detection accuracy and reduces miss rates, it also brings challenges—false positives, workflow disruption, and potential deskilling of endoscopists. The authors urge more robust, randomized trials to evaluate AI’s role in real-world clinical settings.